DSM-Firmenich stock gains as PARSOL Shield wins FDA approval

DSM-Firmenich stock reacts to fresh regulatory news as the company secures FDA approval for its new PARSOL Shield sunscreen active, adding to a portfolio that already delivers strong nutrition and health revenues.

DSM-Firmenich stock (ISIN CH1216478797) is trading higher as of September 4, 2026, with the share price around 75.88 euros on Euronext and up about 0.45% over the last 24 hours, according to data from a TradingView quote overview for the DSFIR ticker as of September 4, 2026.The Euronext DSFIR overview shows the stock consolidating near the mid-70-euro level, giving investors a new regulatory catalyst on top of its established nutrition and health businesses.

PARSOL Shield approval strengthens beauty portfolio

On September 4, 2026, DSM-Firmenich announced that the United States Food and Drug Administration has approved its PARSOL Shield sunscreen active, also known as bemotrizinol, for the US market under the modernized GRASE and Maximal Usage Trial evaluation framework.An article on IndustrySourcing citing DSM-Firmenich highlights that PARSOL Shield is the first new sunscreen active approved in the United States in more than 25 years, putting the company in a leading position in sun care innovation.

According to the same approval note, PARSOL Shield (bemotrizinol) is designed to deliver broad-spectrum UV protection and is positioned within DSM-Firmenich's beauty and personal care segment, which complements its nutrition and health operations.The PARSOL Shield coverage notes that the product is intended for a wide range of sunscreen formulations, which could support incremental revenue and margin improvement in future reporting periods as US formulators adopt the new active.

Portfolio reshaped by Feed Enzymes Alliance sale

Beyond beauty, DSM-Firmenich has been reshaping its portfolio in animal nutrition. On September 3, 2026, sector coverage of feed additives reported that DSM-Firmenich agreed to sell its stake in the Feed Enzymes Alliance to Novonesis for about 1.5 billion euros, with the transaction consolidating research, production and distribution of feed enzymes at Novonesis.A detailed report on Feed Planet Magazine cites the deal size and explains that Novonesis will take over sales and distribution functions previously handled by DSM-Firmenich.

The reported 1.5 billion euros transaction value gives investors a concrete sense of the scale of the divestment and sets up a comparison with DSM-Firmenich's broader business: historical sector studies have highlighted that DSM Nutritional Products, now integrated into DSM-Firmenich, operates as a global giant supplying feed additives including coccidiostats for poultry, reflecting a large installed base in animal nutrition.An IndexBox market outlook on coccidiostats describes DSM Nutritional Products (now DSM-Firmenich) as a global supplier of premixes and vitamins, underlining the strategic importance of the feed business even as specific enzyme assets move to Novonesis.

Nutrition and health remain core earnings drivers

In the broader business context, DSM-Firmenich continues to derive a large share of its revenue from nutrition and health, including animal feed additives, human nutrition ingredients and related solutions. A September 4, 2026 market outlook on coccidiostats for poultry identifies DSM Nutritional Products, now part of DSM-Firmenich, as a global giant in feed additives, particularly anticoccidial premixes and vitamins used in poultry production.The IndexBox analysis reinforces the view that DSM-Firmenich's nutrition business is structurally important for global livestock industries.

While the latest detailed quarterly figures are not explicitly broken out in the day-filtered sources, the combination of a sizeable divestment in feed enzymes and the continued positioning as a top-tier supplier in feed additives suggests that DSM-Firmenich is reallocating capital within its nutrition franchise. For comparison, the 1.5 billion euros Feed Enzymes Alliance stake sale represents a substantial capital pool that can be redeployed into higher-growth or higher-margin segments, such as specialty health ingredients, beauty actives like PARSOL Shield, or innovation in sustainable animal nutrition.

Stock positioning for investors

As of September 4, 2026, DSM-Firmenich stock trades at around 75.88 euros on Euronext, moderately above recent levels that had been hovering near the low-70-euro range according to recent chart views, implying a modest single-digit percent move as the market digests the PARSOL Shield news and portfolio reshaping.The DSFIR quote page indicates that the stock has gained about 0.45% over the last 24 hours, a measured reaction that suggests investors welcome the FDA approval but are also watching execution across nutrition and health businesses.

For investors comparing DSM-Firmenich with regional peers, the Euronext listing offers exposure in euros with liquidity supported by European institutional interest, while the company's global operations span Europe, the Americas and Asia. The divestment to Novonesis in feed enzymes and the new PARSOL Shield approval show how DSM-Firmenich is actively fine-tuning its portfolio across animal nutrition and beauty, aiming to balance stable cash flows from feed and nutrition ingredients with innovation-led growth in health and beauty actives.

PARSOL Shield as a representative product

A concrete example of DSM-Firmenich's innovation strategy is PARSOL Shield, the newly FDA-approved sunscreen active. The product is intended for use in broad-spectrum sunscreen formulations and offers formulators a modern UV filter option that has passed the United States regulatory requirements under the latest GRASE and Maximal Usage Trial standards.Coverage of the FDA approval emphasizes that this is the first new sunscreen active approved in the US in more than 25 years, making PARSOL Shield a flagship product for DSM-Firmenich's beauty and personal care segment and a tangible example of how regulatory advances can open new revenue streams.

DSM-Firmenich stock price snapshot

DSM-Firmenich stock closed around 75.88 euros on Euronext as of September 4, 2026, according to market data compiled on the DSFIR quote overview, with a daily performance of about plus 0.45% and trading firmly within its recent range.The TradingView DSFIR page serves as a reference for investors tracking intraday movements and the broader technical picture. For euro-based investors, the Euronext listing provides a straightforward way to gain exposure to DSM-Firmenich's mix of nutrition, health and beauty businesses without currency translation risks.

DSM-Firmenich at a glance

• Company: DSM-Firmenich AG
• ISIN: CH1216478797
• Ticker: DSFIR
• Trading venue: Euronext Amsterdam
• Price (as of September 4, 2026): 75.88 EUR
• Sector / Industry: Nutrition, health and beauty ingredients
• Index membership: European mid and large-cap indices